Skip to content

US · OABI · BIOTECHNOLOGY

OmniAb, Inc. (OABI) intrinsic value and stock valuation

$4.66as of 2026-11-21 · Mkt cap 241.75M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

OmniAb, Inc. DCF and intrinsic value

InvestorsCraft values OABI with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from OABI’s statements →

OmniAb, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology EmeryVille, CA 94608 omniab.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$18.7M-4.3% 5y CAGRd
20192025
Net income
-$-64.78M
20192025
Free cash flow
-$-37.02M
20192025
Total equity
$267M+2.5% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$18.7M$26.4M$34.2M$59.1M$34.8M
Operating income-$-71.52M-$-74.5M-$-69.42M-$-26.65M-$-35.61M
Net income-$-64.78M-$-62.03M-$-50.62M-$-22.33M-$-27.04M
EPSd-$-570.05K-$-606K-$-507.83K-$-261.72K-$-235.5K
Operating cash flow-$-36.45M-$-39.66M$2.35M-$-3.59M-$-5.67M
Capital expenditure-$-560K-$-1.88M-$-1.64M-$-17.17M-$-4.07M
Free cash flow-$-37.02M-$-41.54M$700K-$-20.75M-$-9.74M
Total assets$300.9M$325.6M$375.2M$421.2M$304.5M
Total debt$20.3M$23.2M$25.6M$25.8M$13.9M
Net debt-$-5.19M-$-4.43M$9.2M-$-7.59M$13.9M
Total equity$267M$287.6M$314.6M$341.4M$234.3M
Cash and short-term investments$54M$59.4M$87M$88.3M$0.00
Income statement
20252024202320222021
Revenue$18.7M$26.4M$34.2M$59.1M$34.8M
Cost of revenue$22.1M$0.00$0.00$0.00$0.00
Gross profit-$-3.39M$26.4M$34.2M$59.1M$34.8M
Research and development expenses$47.8M$55.1M$56.5M$48.4M$39.2M
Selling, general and administrative expenses$29.2M$30.7M$33.3M$24.9M$17M
Other expenses-$-8.84M$15M$13.7M$12.5M$14.2M
Operating expenses$68.1M$100.9M$103.6M$85.7M$70.4M
Cost and expenses$90.2M$100.9M$103.6M$85.7M$70.4M
Interest income$2.66M$3.11M$5.05M$590K$0.00
Interest expense$0.00$0.00$0.00$0.00$10K
Depreciation and amortization$21.8M$23.6M$19.5M$18.3M$16.3M
Ebitda-$-44.54M-$-47.83M-$-44.87M-$-7.81M-$-18.09M
Operating income-$-71.52M-$-74.5M-$-69.42M-$-26.65M-$-35.61M
Total other income/expenses, net$5.22M$3.09M$5.06M$590K$1.26M
Income before tax-$-66.29M-$-71.41M-$-64.36M-$-26.06M-$-34.35M
Income tax expense-$-1.51M-$-9.38M-$-13.74M-$-3.73M-$-7.31M
Net income-$-64.78M-$-62.03M-$-50.62M-$-22.33M-$-27.04M
Weighted average shares outstanding$113.6M$102.4M$99.7M$85.3M$114.8M
Weighted average diluted shares outstanding$113.6M$102.4M$99.7M$85.3M$114.8M
Balance sheet
20252024202320222021
Cash and short-term investments$54M$59.4M$87M$88.3M$0.00
Net receivables$7.39M$5.27M$3.84M$30.3M$21.1M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$65.3M$68.1M$94.9M$125M$22.5M
Property, plant and equipment, net$25M$33.3M$38.1M$41.5M$20.1M
Goodwill and intangible assets$209.1M$222M$239.5M$251.2M$260.3M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$235.6M$257.4M$280.3M$296.3M$281.9M
Total assets$300.9M$325.6M$375.2M$421.2M$304.5M
Accounts payable$1.88M$2.3M$4.41M$2.97M$2.92M
Short-term debt$3.88M$3.78M$3.49M$1.78M$580K
Deferred revenue$3.16M$2.34M$6.85M$8.21M$10.8M
Total current liabilities$16.3M$15.1M$23.1M$26M$20.6M
Long-term debt$16.5M$19.4M$22.1M$24M$13.3M
Deferred revenue, non-current$0.00$120K$860K$4.33M$9.23M
Total non-current liabilities$17.6M$22.9M$37.5M$53.8M$49.6M
Capital lease obligations$20.3M$23.2M$25.6M$25.8M$13.9M
Total liabilities$33.9M$37.9M$60.6M$79.8M$70.2M
Common stock$10K$10K$10K$10K$0.00
Retained earnings-$-166.18M-$-101.4M-$-39.37M$11.3M$0.00
Accumulated other comprehensive income (loss)$10K$30K$50K$10K$234.3M
Total equity$267M$287.6M$314.6M$341.4M$234.3M
Total investments$28.5M$31.8M$70.6M$54.9M$0.00
Total debt$20.3M$23.2M$25.6M$25.8M$13.9M
Net debt-$-5.19M-$-4.43M$9.2M-$-7.59M$13.9M
Cash flow statement
20252024202320222021
Net income-$-64.78M-$-62.03M-$-50.62M-$-22.33M-$-27.04M
Depreciation and amortization$21.8M$23.6M$19.5M$18.3M$16.3M
Stock-based compensation$15.8M$21.5M$24.8M$18.3M$15.1M
Change in working capital-$-4.95M-$-10.17M$24.9M-$-10.83M-$-2.63M
Accounts receivable$190K-$-620K$26.9M-$-12.74M$6.02M
Inventory$0.00$0.00$0.00$0.00-$-1.51M
Accounts payable-$-230K-$-2.41M$920K$15.1M$1.51M
Net cash provided by operating activities-$-36.45M-$-39.66M$2.35M-$-3.59M-$-5.67M
Investments in property, plant and equipment-$-560K-$-1.88M-$-1.64M-$-17.17M-$-4.07M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$6.47M$37.9M-$-18.38M-$-73.31M-$-4.03M
Common stock issued$28.4M$11.4M$0.00$96.2M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$27.9M$13M-$-890K$110.7M$9.7M
Net change in cash-$-2.07M$11.2M-$-16.92M$33.4M$0.00
Cash at end of period$26.1M$28.2M$16.9M$33.4M$0.00
Operating cash flow-$-36.45M-$-39.66M$2.35M-$-3.59M-$-5.67M
Capital expenditure-$-560K-$-1.88M-$-1.64M-$-17.17M-$-4.07M
Free cash flow-$-37.02M-$-41.54M$700K-$-20.75M-$-9.74M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About OmniAb, Inc.

        OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.

        CEO
        Matthew W. Foehr
        Employees
        89
        Beta
        1.17

        Explore

        Frequently asked questions

        What is the intrinsic value of OmniAb, Inc. (OABI)?

        OmniAb, Inc. (OABI) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is OABI undervalued?

        OABI trades at a price of $4.66 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.